Agila

Regulatory claims on Agila settled, says Strides Shasun

There was some regulatory overhangs post Strides-Mylan Agila transaction, says Arun Kumar, Executive VC & MD of Strides Shasun.

Strides Arcolab up 2%; Macquarie sees 100% return over 3-yr

According to the brokerage, Strides Arcolab is an emerging leader that can potentially generate a 100 percent return over 3 years. US approval and merger synergies are key catalysts for the stock.

Special dividend of Rs 500/share to cost us $525mn: Strides

Strides Arcolab has a fairly strong organic growth strategy in place at the moment, says Group CEO & VC Arun Kumar.

Strides jumps 8.5%, may pay out Rs 800/sh to shareholders

According to information available in BSE, Strides Acrolab has 27,177 shareholders, including 24,320 retail investors. As of June 30, the promoters had a 27.39 percent stake in the company, while foreign institutional investors had 51.7 percent.

Strides Arcolab up 5%, gets US FDA nod for Italian facility

Strides is developing a portfolio of liquids and semi-solids products for the US and EU markets. Currently it has over 12 products at various stages of developments and approvals. The drug maker already sells semi-solids in the UK market.